Check patentability & draft patents in minutes with Patsnap Eureka AI!

Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism

A technology of gene polymorphism and determination method, which is applied in the field of determining the risk of occurrence of side effects of anticancer drug therapy including the step of detecting MUC4 gene polymorphism, and can solve problems such as death

Inactive Publication Date: 2015-10-28
SAITAMA MEDICAL UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, not only the Japanese, but not to mention the frequency overseas, there are also cases of death due to side effects of medicines, which is a major problem

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism
  • Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism
  • Method for evaluating side-effect onset risk in anticancer drug treatment, including detecting muc4 gene polymorphism

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0089]

[0090] Samples from 262 patients with drug-induced lung injury and 180 patients with interstitial lung disease, that is, a total of 442 patients, were collected from 30 auxiliary medical institutions across the country.

[0091] Among them, 180 patients with interstitial lung disease included 141 patients with acute exacerbation of IPF.

[0092] In addition, 262 patients with drug-induced lung injury included the following cases.

[0093] 49 patients with interstitial lung disease (ILD) caused by Iressa or Tarceva (hereinafter referred to as "Iressa ILD + Tarceva ILD"),

[0094] 3 patients with interstitial lung disease (ILD) (hereinafter referred to as XALCORI ILD) caused by XALCORI,

[0095] 38 patients with interstitial lung disease (ILD) caused by Taxotere (hereinafter referred to as Taxotere ILD)

[0096]

[0097] Among the above 442 cases, patient data + patient images were collected for 279 cases, and the diagnosis was confirmed. Among them, centering on...

Embodiment 2

[0100] (Example 2)

Embodiment 2－1

[0101] (Example 2-1)

[0102] For all the polymorphisms of 180215 mentioned above, the correlation analysis was carried out between 36 "Iressa ILD+Tarceva ILD" patients and 70 general Japanese. The result is as figure 1 shown. Bonferroni correction was performed, and a P value of 0.001 / 180215 or less was considered significant.

[0103] We believe, figure 1 In , isolated spots may also be an artifact caused by differences in the exon capture efficiency of each kit. Furthermore, we argue that points are aggregated into steeple-like parts contained in points (e.g., figure 1 The positions indicated by the middle arrows) indicate that in broad chromosomal regions, there is a difference in the frequency of polymorphisms between the two groups, showing a high probability of a true association.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide an evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage due to such factors as anticancer drug administration. The purpose of the present invention is also to provide a method for evaluating the risk of onset of side effects in anticancer drug treatment. An evaluation method and evaluation kit for evaluating the risk of onset of diffuse alveolar damage, including detecting gene polymorphism present in the MUC4 gene. A method for evaluating the risk of onset of side effects in anticancer drug treatment, including detecting gene polymorphism present in the MUC4 gene of a patient scheduled for anticancer drug administration.

Description

technical field [0001] The present invention relates to: (1) a method for determining the risk of diffuse alveolar damage, including the step of detecting the polymorphism of the MUC4 gene; (2) a method for determining the risk of side effects of anticancer drug therapy, including detecting the MUC4 gene A step of detecting the polymorphism; and (3) a kit used in the above determination, etc. Background technique [0002] Administration of anticancer agents such as Iressa (generic name: gefitinib) and Tarceva (generic name: erlotinib) sometimes causes a serious side effect called diffuse alveolar damage. In addition, acute exacerbations of idiopathic pulmonary fibrosis sometimes cause a serious side effect called diffuse alveolar damage. Diffuse alveolar damage shows resistance to treatment, and is recurrent, and worsens repeatedly during treatment, and worsens and becomes severe at an early stage, so it is one of the symptoms that must be paid close attention to. [0003]...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12N15/09
CPCC12Q1/6886C12Q2600/142C12Q2600/156A61K31/337A61K31/4545A61K31/4745A61K31/517A61K31/519A61K31/5377A61K31/7068C12Q2600/106
Inventor 荻原弘一宫泽仁志椎原淳田中知明井上庆明
Owner SAITAMA MEDICAL UNIVERSITY
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com